Venus Remedies Limited, a leading global pharmaceutical company, has successfully renewed its Good Manufacturing Practices (GMP) certification from Ukraine’s State Service on Medicines and Drugs Control (SMDC). This certification renewal applies to the company’s Unit-II manufacturing facility located in Baddi, Himachal Pradesh, which produces critical formulations including cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral products, encompassing both liquid and lyophilized injections.

This renewed GMP certification reinforces Venus Remedies’ unwavering commitment to maintaining world-class manufacturing standards that meet stringent global quality requirements. Saransh Chaudhary, President of Global Critical Care at Venus Remedies and CEO of Venus Medicine Research Centre, noted that this milestone not only secures their foothold in the Ukrainian pharmaceutical market but also enables enhanced penetration into other Pharmaceutical Inspection Cooperation Scheme (Plc/S) member countries.

Ukraine’s membership in the Pharmaceutical Inspection Cooperation Scheme (Plc/S) — a consortium comprising 56 countries across Europe, Asia, Oceania, and the Americas — significantly boosts the strategic value of this certification. Venus Remedies already maintains a strong presence in 32 Plc/S countries, including South Africa, Thailand, Malaysia, Saudi Arabia, and Australia, and aims to further expand its footprint.

The Ukrainian pharmaceutical market is poised for steady growth with a projected CAGR of 3.9%, expected to reach USD 822.26 million by 2029. This growth is primarily driven by rising demand for generics and oncology treatments. With over two decades of operational experience in Ukraine and 44 registered products, Venus Remedies views this certification renewal as critical for sustaining growth and widening access across the broader Asia and Commonwealth of Independent States (CIS) region.

Aditi K. Chaudhary, President of International Business at Venus Remedies, emphasized the importance of Ukraine as a strategic market. She stated that the renewed GMP certification enhances the company’s credibility with regional regulators and partners, enabling portfolio expansion and delivery of high-quality medicines to a broader patient base.

Venus Remedies’ Baddi Unit-II facility is equipped with state-of-the-art infrastructure and cutting-edge technology designed to meet complex therapeutic needs and evolving global healthcare demands. The company’s commitment to quality is demonstrated by its extensive international manufacturing credentials, which include GMP approvals from EU-GMP (INFARMED), Plc/S members (Malaysia and Ukraine), SAHPRA (South Africa), UNICEF, TGA (Australia), INVIMA (Colombia), and WHO-GMP standards.

In addition to manufacturing excellence, Venus Remedies holds key ISO certifications for quality management (ISO 9001), environmental management (ISO 14001), and occupational health and safety (ISO 45001), reflecting its adherence to global best practices across operational facets.

About Venus Remedies Limited

Headquartered in Panchkula, Haryana, Venus Remedies Limited (NSE: VENUSREM, BSE: 526953) is among the world’s top 10 manufacturers of fixed-dose injectable pharmaceuticals. With a presence in over 90 countries, its product portfolio includes 75 offerings marketed across Europe, Australia, Africa, Asia-Pacific, Commonwealth states, the Middle East, Latin America, and the Caribbean. The company operates nine globally benchmarked facilities in Panchkula, Baddi (India), and Weme (Germany), supported by 11 overseas marketing offices.

Venus Remedies is a pioneer in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company develops advanced antibiotics and β-lactam/β-lactamase inhibitor combinations to address multidrug-resistant pathogens. Its initiatives such as GASAR provide critical data on antibiotic resistance, while the PLEA Trust promotes antibiotic stewardship. Venus Remedies is an active member of the AMR-Industry Alliance, India AMR Innovation Hub, and Vigily AMR Registry, playing a pivotal role in shaping global AMR research and policies.

The Upcoming IPOs in this week and coming weeks are Neptune Petrochemicals, Aegis Vopak Terminals, Schloss Bangalore, Astonea Labs, Nikita Papers, Prostarm Info Systems, Victory Electric Vehicles International, Blue Water Logistics, Wagons Learning.

The Current active IPO are Unified Data - Tech Solutions, Dar Credit and Capital, Belrise Industries, Borana Weaves.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.